New Data Provide Further Evidence of Lung Function Improvemen?ts in Severe Asthma with Tiotropium Delivered via the Respimat Inhaler
Boehringer Ingelheim has presented the latest data for tiotropium in asthma at the 2013 American College of Chest Physicians (ACCP) annual meeting (CHEST 2013) in Chicago.
The CHEST session "Tiotropium and Asthma" features a total of four oral presentations from Phase II and III studies of tiotropium delivered via the Respimat inhaler in severe asthma patients. Tiotropium is currently being evaluated to determine the efficacy and safety in treating asthma patients and is not currently approved for this indication.
Pooled Phase III data being presented from the replicate PrimoTinA-asthma studies (NCT00772538 and NCT00776984) provide further evidence for tiotropium delivered via the Respimat inhaler as a possible add-on treatment for severe persistent asthma.
Data presented at CHEST show that in adult asthma patients who remain symptomatic despite treatment with at least inhaled corticosteroids (ICS)/long-acting beta-2 agonists (LABA), tiotropium delivered via the Respimat inhaler reduced the risk of severe asthma exacerbations and any asthma exacerbation. These results add to data from the ongoing Phase III trial programme that has previously shown positive results for tiotropium in severe asthma patients who remained symptomatic despite treatment with at least ICS/LABA.
"There is a serious unmet need for additional therapies for severe asthma patients who remain symptomatic and experience exacerbations despite current treatment," said Donald P. Tashkin, MD, emeritus professor of medicine, David Geffen School of Medicine at UCLA, Los Angeles, and lead author on one of the presentations. "The data being presented at CHEST add further evidence of the potential of tiotropium in treating severe symptomatic asthma."
Asthma exacerbations (or attacks) occur in patients across all degrees of asthma severity and are an important cause of asthma-related morbidity and mortality.
"The CHEST session featuring four oral presentations communicating the clinical trial results of tiotropium, is a testament to the breadth and depth of our UniTinA-asthma programme and the company's leadership position in developing new therapies for lung diseases," said Tunde Otulana, MD, senior vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We at Boehringer Ingelheim are committed to developing new treatments for the growing number of asthma patients who remain symptomatic despite current therapy and are encouraged by these additional findings."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance